Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)

SHA:688062 Revenue

Mabwell (Shanghai) Bioscience had revenue of 185.04M CNY in the quarter ending June 30, 2026, with 228.23% growth. This brings the company's total for the last twelve months to 873.99M, up 371.36% year-over-year. In the year 2025, Mabwell (Shanghai) Bioscience had annual revenue of 662.52M with 231.62% growth. That makes Mabwell (Shanghai) Bioscience the 20,644th largest company in the world by revenue and 3,775th in China.

• Revenue (ttm): 873.99M
• Revenue Growth: +371.36%
• P/S Ratio: 10.81
• Revenue / Employee: 644.54K
• Employees: 1,356
• Market Cap: 9.67B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• Mainland China 582.13M 87.9%
• Other Regions 80.38M 12.1%

Fiscal year ended Dec 31, 2025 See the full SHA:688062 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	662.52M	462.73M	231.62%
Dec 31, 2024	199.78M	71.95M	56.28%
Dec 31, 2023	127.84M	100.11M	361.03%
Dec 31, 2022	27.73M	11.50M	70.88%
Dec 31, 2021	16.23M	10.92M	206.03%

Data Source: S&P Global Market Intelligence Last updated: Aug 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 21, 2026

Data Sources Report a data error